A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
收藏DataCite Commons2026-03-02 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003009/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with moderately to severely active ulcerative colitis (UC).
提供机构：
Vivli
创建时间：
2018-10-27
